CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer

PURPOSE: Patients with pancreatic ductal adenocarcinoma (PDAC) who undergo surgical resection and adjuvant chemotherapy have an expected survival of only two years due to disease recurrence, frequently in the liver. We investigated the role of liver macrophages in progression of PDAC micrometastases...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Michaels, Alex D., Newhook, Timothy E., Adair, Sara J., Morioka, Sho, Goudreau, Bernadette J., Nagdas, Sarbajeet, Mullen, Matthew G., Persily, Jesse B., Bullock, Timothy N. J., Slingluff, Craig L., Ravichandran, Kodi S., Thomas Parsons, J., Bauer, Todd W.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6296745/
https://ncbi.nlm.nih.gov/pubmed/29288236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2283
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge